Icon

Inrebic - (100 mg; Capsule)

Fedratinib Hydrochloride Impact
100 mg; Capsule
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
INREBIC is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Yes
*** *********** **** ****** ** *** **, ****. ****** ************, ***., ** * ******-***** ********** ** ******* ***********. ***** *** **** **** ** **- *****://***.***.***/**?***=/********/*****/****/*****/******************/***-********.***
Inrebic Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
**** ******* **** *** ******* **** *** ******* **** *** ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ********* *** **, **** ******* **** ******* *** **** *** **** ****
  1. *** **, **** : **** ** ** ***** *** ***** ** *** ***.
  2. *** **, **** : **** ******** ****** ** ***** **** ** ****** **** ******* ** '***, *** '***.
  3. *** **, **** : ****** **** **** **** ************ ** ****** ** '***, *** '***.
  4. *** **, **** : ********* ** **'* ******* *********, ****** *** **** ******* ********** **** ************ ** ******* '*** *** '***. ****** ****** **** ** **** ********** **** **** **********.
  5. : ** *** *** - ****** ****** **** *** ****** '*** *** *** *** **** *** **, ****. (*****://***.***.***/**?***=/********/*****/****/*****/******************/***-********.***)

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.